Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: luis a. garcia who wrote (867)	1/20/1998 11:59:00 AM
From: MCorbley	Read Replies (1) \| Respond to of 1115

Would anyone care to speculate on how much money Lidak would need to set up its own production of Lidakol and begin the marketing? Last year they lost $11 million and some of that was due to the clinical trial. According to the 10-K, they have cash, cash equivalents and short-term investments totaling $14.4 million and working capital of $11.3 million. They also made the statement: "The Company estimates its current cash requirements to be sufficient to fund operating activities for fiscal 1998." That statement presumably reflects the assumption that Bristol-Meyers was going to fund much of the production and marketing. My feeling is that once Lidakol is on the market, it will rapidly generate enough revenue to support all future activities of the company. So the question is: How much money do they really need to bring it to market? Do they need $80-130 million offered by HealthMed?